Your browser doesn't support javascript.
Effects of the COVID-19 pandemic on heart failure hospitalizations in Japan: interrupted time series analysis.
Morishita, Tetsuji; Takada, Daisuke; Shin, Jung-Ho; Higuchi, Takuya; Kunisawa, Susumu; Fushimi, Kiyohide; Imanaka, Yuichi.
  • Morishita T; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, 606-8501, Japan.
  • Takada D; Department of Internal Medicine, Matsunami General Hospital, Gifu, Japan.
  • Shin JH; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, 606-8501, Japan.
  • Higuchi T; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, 606-8501, Japan.
  • Kunisawa S; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, 606-8501, Japan.
  • Fushimi K; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, 606-8501, Japan.
  • Imanaka Y; Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
ESC Heart Fail ; 9(1): 31-38, 2022 02.
Article in English | MEDLINE | ID: covidwho-1575095
ABSTRACT

AIMS:

The Coronavirus Disease 2019 (COVID-19) pandemic has had unprecedented effects on health care utilization for acute cardiovascular diseases. Although hospitalizations for acute coronary syndrome decreased during the COVID-19 pandemic, there is a paucity of data on the trends and management of heart failure (HF) cases. Furthermore, concerns have been raised that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase susceptibility to COVID-19. This study aimed to elucidate changes in HF hospitalizations from the COVID-19 state of emergency in Japan and investigated changes in the prescription of ACEIs and ARBs, and in-hospital mortality. METHODS AND

RESULTS:

We performed an interrupted time series analysis of HF hospitalizations in Japan to verify the impacts of the COVID-19 state of emergency. Changes in the weekly volume of HF hospitalizations were taken as the primary outcome measure. Between 1 April 2018 and 4 July 2020, 109 429 HF cases required admission. After the state of emergency, an immediate decrease was observed in HF cases per week [-3.6%; 95% confidence interval (CI) -0.3% to -6.7%, P = 0.03]. There was no significant change in the prescription of ACEIs or ARBs after the state of emergency (4.2%; 95% CI -0.3% to 8.9%, P = 0.07). The COVID-19 pandemic had no effect on in-hospital mortality among HF patients (5.3%; 95% CI -4.9% to 16.6%, P = 0.32).

CONCLUSIONS:

We demonstrated a decline in HF hospitalizations during the COVID-19 pandemic in Japan, with no clear evidence of a negative effect on the prescription of ACEIs and ARBs or in-hospital mortality.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Heart Failure Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: ESC Heart Fail Year: 2022 Document Type: Article Affiliation country: Ehf2.13744

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Heart Failure Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: ESC Heart Fail Year: 2022 Document Type: Article Affiliation country: Ehf2.13744